Skip to main content
SpringerLink
Log in

CARDIOVASCULAR DISEASE

A novel treatment for heart failure targets myocardial fibrosis

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A new trial suggests that pirfenidone, an approved treatment for idiopathic pulmonary fibrosis, may also reduce myocardial fibrosis in patients with heart failure who have a preserved left ventricular ejection fraction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Pathways that lead to myocardial fibrosis.

References

  1. Lewis, G. A. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01452-0 (2021).

    Article  Google Scholar 

  2. Cleland, J. G. F. et al. Eur. Heart J. 42, 2331–2343 (2021).

    Article  Google Scholar 

  3. Pellicori, P. et al. Eur. J. Heart Fail. https://doi.org/10.1002/ejhf.2220 (2021).

    Article  PubMed  Google Scholar 

  4. Pellicori, P. et al. Eur. J. Heart Fail. 22, 1711–1723 (2020).

    Article  CAS  Google Scholar 

  5. Pellicori, P. et al. Cardiovasc. Res. 116, 91–100 (2020).

    Article  CAS  Google Scholar 

  6. Cleland, J. G. F. et al. Eur. Heart J. 39, 26–35 (2018).

    Article  CAS  Google Scholar 

  7. Cleland, J. G. F. et al. Eur. Heart J. 42, 684–696 (2020).

    Article  Google Scholar 

  8. Gonzalez, A., Schelbert, E. B., Diez, J. & Butler, J. J. Am. Coll. Cardiol. 71, 1696–1706 (2018).

    Article  Google Scholar 

  9. Aimo, A. et al. Pharmacol. Res. 155, 104694 (2020).

    Article  CAS  Google Scholar 

  10. Lopez, B. et al. J. Am. Coll. Cardiol. 67, 251–260 (2016).

    Article  CAS  Google Scholar 

  11. Lopez, B. et al. Nat. Rev. Cardiol. 18, 479–498 (2021).

    Article  Google Scholar 

  12. Mason, T. et al. JACC Cardiovasc. Imaging 14, 1164–1173 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK

    John G. F. Cleland & Pierpaolo Pellicori

  2. Program of Cardiovascular Diseases, CIMA. Universidad de Navarra and IdiSNA, Pamplona, Spain

    Arantxa González

  3. CIBERCV, Carlos III Institute of Health, Madrid, Spain

    Arantxa González

Authors
  1. John G. F. Cleland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierpaolo Pellicori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arantxa González
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John G. F. Cleland.

Ethics declarations

Competing interests

J.G.F.C. has received research funding from Torrent Pharmaceuticals, which has an advanced glycation-end-product breaker in development.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cleland, J.G.F., Pellicori, P. & González, A. A novel treatment for heart failure targets myocardial fibrosis. Nat Med 27, 1343–1344 (2021). https://doi.org/10.1038/s41591-021-01457-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-021-01457-9

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation